Immune cells produced during severe COVID-19 infection may shrink tumors. The unexpected mechanism offers a new therapeutic possibility for advanced and treatment-resistant cancers.

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

The WVU Cancer Institute at United Hospital Center (UHC) is offering CYTALUX® (pafolacianine), a groundbreaking imaging agent ...